UK: Actavis v Eli Lilly

Last Updated: 23 November 2017
Article by Gwilym Roberts

What patent attorneys and examiners need to know about the UK's, and perhaps Europe's, biggest infringement case for 12 years.

 With the recent decision in Actavis v Eli Lilly Lord Neuberger has rethought, and rewritten, the rules of infringement. After 35 years of doctrinal development going back to the legendary Catnic case and seemingly settled in Kirin-Amgen in 2005, the Supreme Court has injected a nitro boost and taken the lead in establishing a test applicable across Europe. Litigators are going wild for it, but it is vital to look at the challenge that has been laid down to the patent makers, getters and even granters as it could have major ramifications for the day job.

The basics of the case

Eli Lilly were working on Pemetrexed, which is conventionally used to treat tumours in its free acid form - which is toxic. After a very broad initial claim to use of a methylmalonic acid, and the usual added matter wranglings at the EPO, claims were granted to Eli Lilly directed to a specific salt, Pemetrexed disodium - which is less toxic. Actavis used different Pemetrexed salts with the same effect. "A fight ensued, which presumably wouldn't have happened if an amendment had been available to 'a Pemetrexed salt' and it went all the way to the Supreme Court."

The decision

It looks like Lord Neuberger felt that there was infringement, and that infringement would be found in other European jurisdictions. But, application of the UK's current 'Protocol questions' (Reminder: is there an immaterial variant? Would that have been obvious at the publication date? Was strict compliance intended nonetheless?) would not deliver that result.

The old test

The Catnic-to-Kirin-Amgen suite of cases tells us that you shouldn't do the following: 1) look for literal infringement; 2) if that doesn't catch the infringement, apply the Protocol questions. Instead, there is supposed to be a 'single cause of action'. You just interpret the claim and work out what it is intended to mean, kind of in vacuo and without knowledge of the infringement's effects. That approach has been criticised in the past and probably isn't what anyone does, though they will pay lip service to it.

The new test

Here, Lord Neuberger has effectively said 'what about the Protocol to Art.69 EPC - which the Protocol questions are supposed to reflect? It is directed to determining the extent of protection, not to interpreting a claim, and it mentions equivalents!' He holds that shoehorning the equivalents issue via the 'immaterial variants' aspect into a single interpretation step can lead to errors. Instead, we should now interpret and if that doesn't settle it, apply a more equivalents-driven variant of the Protocol questions (step two above) to determine the extent of protection. We're also allowed knowledge of the result achieved by the variant.

The new test in this case – equivalents

The facts in this case give a good illustration and, given that the revised approach reflects what many practitioners were probably inadvertently doing anyway, is unlikely to be dismissed as being fact or technology specific.

First, the interpretation step. The Actavis product did not use Pemetrexed disodium, but neat Pemetrexed or different salts thereof. These do not infringe on a normal interpretation of the claim.

Second, the three revised Protocol questions. The first reformulated question is relatively unchanged and could be paraphrased as 'is it an equivalent?' The judge held that the Actavis products achieved substantially the same result in substantially the same way - so yes.

The second Protocal question caused the most problems. Under the old approach there would not have been infringement because the unpredictability of substituting other salts means that it would not have been obvious at the date of the patent that the Actavis product was an immaterial variant. Neuberger disliked this, as it showed the artificiality of treating this purely as a matter of interpretation.

He preferred a more pragmatic approach, stripped out the time limitation and effectively asked "can you tell from the patent, with knowledge at the date of infringement, whether it's an equivalent (ie. you don't have to guess if it works, and you can consider recent developments in the technology)?". Therefore, in the present case, the question wasn't 'might it have been obvious that other salts are an immaterial variant?', but 'given that the other salts achieve the same result, would it be obvious that they did so in the same way?'. Based on the facts, his answer again was 'yes'.

The third Protocol question of 'strict compliance' is still largely applicable, and could be expressed as 'did the patent nonetheless exclude the equivalent?'. Thankfully, this was considered from the perspective of the whole specification and again at the infringement date. Infringement was found.

Relevance of the file history

We'll look at what this means for patent attorneys below, but the change that has more immediate implications stems from the judge's consideration of the EP file history. The instruction is that we should now consider it, but 'sceptically', and only where it unambiguously resolves a point, or is in the public interest (e.g. where the patentee had expressly excluded an interpretation during prosecution). Having said that, Lord Neuberger used the file history for confirmatory purposes here; the original claims were broad; the permitted amendment to Pemetrexed disodium was occasioned by intermediate generalisation objections, and so strict compliance isn't required.

This has implications both for drafting and prosecution (and although it doesn't affect the decision, practitioners may agree that the evidence given to Lord Neuberger on the operation of the EPO may have been a little sketchy), so patent examiners might be interested to read the relevant passages of the decision too.

What does this mean for a patent attorney?

  1. The test for infringement really is more pragmatic. You can expressly use knowledge of the invention and you can read the patent sensibly and assess whether there is an immaterial variant. In terms of certainty, there was always an argument that consulting the file history was a step too far. But, surely everyone already has a glance at it. Also, the most convincing argument against taking it into account appears to have been Lord Hoffman's statement, 'life is too short'! That was back in 2005, but accessing the file is now a matter of a couple of clicks, at least at the EPO. As long as we are not entering an era of pitched battles about what the content of a file history means, this seems a welcome development.
  2. Judging by the 'light touch' level of knowledge of what goes on at the EPO prosecution level, in this particular case, practitioner knowledge may be absolutely vital in analysing the file. We therefore may see more attorneys appearing as experts in this area.
  3. Less welcome is the impact on our daily practice before Patent Offices. What's done is done, and it's probably best not losing sleep about existing skeletons in closets. There is no suggestion that anything but the immediate file history is considered relevant (but of course someone is going to try and cite patent family members in other jurisdictions).

    Besides, we're usually so aware of the potential impact of statements here in, say, US equivalent proceedings that we're pretty careful anyway. Naturally, we should avoid statements expressly excluding certain interpretations - we have Lord Neuberger's clear guidance on that.

    Note, however, that unlike in many jurisdictions, the use of a limiting amendment did not restrict the scope of the claim. The judge looked at the original broad claim, concluded that strict restriction to a particular Pemetrexed salt was not intended, and then extended the claim scope more broadly than the eventual allowed wording on that basis.

    However, the context and presentation of the amendment here were relevant. As it was required to overcome an intermediate generalisation objection (to the judge's apparent bemusement) there were no limiting statements in the accompanying submissions that might otherwise have caused problems. In essence, when making any amendment or statement to the office in the future, the attorney should imagine the judge reading it and drawing inferences about the patentee's intent.

  4. When it comes to drafting, the importance of dealing with potential added matter issues arises once again. Put in as much basis as you can, and consider a 'pyramid' of terminology from the broadest expression of a feature, through intermediate or alternative formulations, to the narrowest. The reality is that the perfect wording is usually only available in hindsight, as was undoubtedly the case here, and you could take comfort from the fact that in the end the court generously generalised the eventual term. Or you could consider how much cheaper it would have been to have been literally infringed...


This is an important decision, and it is useful to consider its impact not just on litigators, but prosecutors, drafters and even examiners. Current best practice may not have changed too much, but every interaction with the patent office now carries just a little more weight, and the 'how would a judge read this' test needs to become second nature when formulating a response. At the broader level, it feels like a welcome clarification or confirmation of a practical application of the infringement determination tests, despite the extra pressure on patent attorneys. We will wait to see if this more 'pragmatic' approach develops not just in the UK but across Europe, and turns out to be as significant as it looks.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions